Abstract:TGF-β and related growth factors activate a broad range of cellular responses and play key roles in the pathogenesis of many diseases especially cancer, fibrotic diseases, autoimmune diseases, and parasitic diseases. The activity of the TGF-β-initiated signaling pathway is tightly controlled, for example, through regulation of the key downstream SMAD tumor suppressors. In response to TGF-β, SMADs are phosphorylated, which triggers a series of downstream signaling and gene transcriptional events in the nucleus. To maintain proper levels of activated SMADs, activated SMADs in the nucleus are normally dephosphorylated by nuclear phosphatase PPM1A and then transported back into the cytoplasm. However, it remains elusive how dephosphorylated SMADs are exported out of the nucleus to ensure the completion of the SMAD signaling termination. Objective: To discover and characterize the underlying pathway that completes the step of SMAD signaling termination. Methods: A combinatorial approach using biochemical, cell biological, and developmental methods was used in this study. Cells were manipulated with expression plasmids for various SMADs, PPM1A, and potential nuclear exporter RanBP3. Xenopus embryos were manipulated using standard protocols. The level of phosphorylated SMADs was performed by western blotting. Nuclear export of SMADs was examined by immunofluorescence microscopy, cell lysate fractionation and a novel reporter assay. Protein-protein interaction of SMADs and RanBP3 was assessed by biochemical assays (e.g. IP-Western) or fluorescence assays. Results: We determined the essential function of RanBP3 in selective nuclear export of SMAD2/3 in the TGF-β pathway. RanBP3 directly recognized dephosphorylated SMAD2/3, which results from the activity of nuclear SMAD phosphatase PPM1A; PPM1A enhanced the physical interaction between RanBP3 and SMAD2/3. We clearly demonstrated that RanBP3 mediated nuclear export of SMAD2/3 in a small G protein Ran-dependent manner. Consequently, increased expression of RanBP3 inhibited TGF-β signaling in mammalian cells and Xenopus embryos, and depletion of RanBP3 expression or dominant negative inhibition of RanBP3 enhanced TGF-β-induced anti-proliferative and transcriptional responses. Finally, we have found that RanBP3 itself was phosphorylated in response to mitogenic growth signals and this phosphorylation could fine-tune the function of RanBP3 in exporting SMADs. Conclusion: We have defined a key role for RanBP3 in selectively mediating SMAD nuclear export and terminating TGF-β signaling. Thus, our finding should provide insights into the mechanisms of TGF-β anti-cancer actions. Knowledge gained from these studies will be used to design novel therapeutic strategies for prevention and treatment of human cancer.

Nuclear Export of Smads by RanBP3L Regulates Bone Morphogenetic Protein Signaling and Mesenchymal Stem Cell Differentiation.

Nuclear Export of Smad2 and Smad3 by RanBP3 Facilitates Termination of TGF-β Signaling

Tgf-Beta and Bmp Signaling in Osteoblast, Skeletal Development, and Bone Formation, Homeostasis and Disease

Coupled Actions of PPM1A and RanBP3 Terminate TGFβ/SMAD Tumor Suppressor Functions

PPM1A dephosphorylates RanBP3 to enable efficient nuclear export of Smad2 and Smad3.

Retinoic Acid Regulates Bone Morphogenic Protein Signal Duration By Promoting The Degradation Of Phosphorylated Smad1

C-terminal Domain (CTD) Small Phosphatase-like 2 Modulates the Canonical Bone Morphogenetic Protein (BMP) Signaling and Mesenchymal Differentiation Via Smad Dephosphorylation*

Arginine Methylation of R81 in Smad6 Confines BMP-induced Smad1 Signaling

Specific control of BMP signaling and mesenchymal differentiation by cytoplasmic phosphatase PPM1H

Bone morphogenetic protein 2 activates Smad6 gene transcription through bone-specific transcription factor Runx2.

Suppression of Tumor Necrosis Factor-mediated Apoptosis by Nuclear Factor Κb-Independent Bone Morphogenetic Protein/Smad Signaling

BMPRIA is required for osteogenic differentiation and RANKL expression in adult bone marrow mesenchymal stromal cells

[The Role of Smads and Related Transcription Factors in the Signal Transduction of Bone Morphogenetic Protein Inducing Bone Formation].

Bone Morphogenetic Protein-Smad Pathway As Drug Targets for Osteoporosis and Cancer Therapy

LMCD1 Promotes Osteogenic Differentiation of Human Bone Marrow Stem Cells by Regulating BMP Signaling

Smad1 Stabilization and Delocalization in Response to the Blockade of BMP Activity

Coupling of dephosphorylation and nuclear export of Smads in TGF-beta signaling.

Opposing TNF-α/IL-1β- and BMP-2-activated MAPK Signaling Pathways Converge on Runx2 to Regulate BMP-2-induced Osteoblastic Differentiation

CXCL12/CXCR4 Signal Axis Plays an Important Role in Mediating Bone Morphogenetic Protein 9-Induced Osteogenic Differentiation of Mesenchymal Stem Cells

Retraction Note To: Schnurri-3 Regulates BMP9-induced Osteogenic Differentiation and Angiogenesis of Human Amniotic Mesenchymal Stem Cells Through Runx2 and VEGF

Lncrna Rmst Acts As an Important Mediator of BMP9-induced Osteogenic Differentiation of Mesenchymal Stem Cells (mscs) by Antagonizing Notch-targeting Micrornas.